Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Ensem Therapeutics
AstraZeneca
Mayo Clinic
Kivu Bioscience Inc.
AstraZeneca
Tubulis GmbH
Eli Lilly and Company
EMD Serono
Arcus Biosciences, Inc.
Sumitomo Pharma America, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Radiopharm Theranostics, Ltd
Seagen Inc.
Bayer